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http:WHAT THIS PAPER ADDS
Retroperitoneal conduit to establish access in cases of small-diameter or torturous iliac vessels is an established
practice that makes endovascular repair possible. Although use of conduits should be liberal to minimize access
site complications, data regarding the outcome after use of conduits is limited. The present paper presents for
the ﬁrst time data from a large cohort of patients using a national registry, thus reﬂecting real-world data and
not data captured from use of devices within clinical trials.Objectives: Challenging iliac access during thoracic endovascular aortic repair (TEVAR) is associated with a higher risk
of access site complications suchas injuryor rupture of the iliac vessels. As a result, the useof iliac conduits is frequently
used to facilitate access during TEVAR. This report evaluates the effect of iliac conduits on TEVAR outcomes.
Methods: The 2005e2010 American College of Surgeons Surgical Quality Improvement Program database was
queried to identify vascular patients undergoing elective TEVAR. Patients without conduit (Group A) were
compared to patients who underwent TEVAR with conduit (Group B).
Results: We identiﬁed 1037 patients (90%) in Group A (69  12.7 years, 42% female) and 117 patients (10%) in
Group B (70  12.6 years, 68% female). Women received conduits more often than men (Male:5.8%,
Female:15.7%, p < 0.001). There was no signiﬁcant difference in the rate of non-surgical
(A:19%,B:25%,p ¼ 0.121), pulmonary (A:11%,B:16%, p ¼ 0.115), renal (A:3.1%, B:1.7%, p ¼ 0.4) and
cardiovascular complications (A:8%, B:12%, p ¼ 0.143) between groups. However, any complication (A:24%,
B:33%. p ¼ 0.025), surgical complications (A:10%, B:16%, p ¼ 0.035) and mortality (A:4.5%, B:12%. p ¼ 0.001)
were signiﬁcantly higher in Group B. In multivariate analysis, use of conduit was associated with a 3.8 times
higher risk of death compared with no conduit after controlling for confounders. Length of in-hospital stay was
similar for both groups (A:6.6  8.8, B:7.6  8 days, p ¼ 0.247). The use of conduits had a declining rate over
time from 17.9% in 2006 down to 6.5% in 2010.
Conclusions: Female patients more frequently require iliac conduits during TEVAR compared to men. Conduits
were associated with a higher rate of surgical complications and mortality. The incidence of conduit use has
decreased threefold in the last ﬁve years. Safer access for TEVAR by use of a conduit should not be abandoned based
on these results, but there should be a heightened awareness for the higher rate of mortality in these patients.
 2013 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Thoracic endovascular aortic repair (TEVAR) has emerged as
an important treatment option for several thoracic aortic
pathologies providing a signiﬁcantly lower perioperative
morbidity and mortality especially in high-risk patients.1e4
Despite the evolution of TEVAR since its FDA approval inof original article: http://dx.doi.org/10.1016/j.ejvs.2012.12.016
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//dx.doi.org/10.1016/j.ejvs.2013.01.0372005, achieving safe and adequate access for stent graft
introduction remains a critical intraoperative issue. Trans-
femoral route for device delivery remains the conven-
tional procedure with feasibility in 70% of cases5,6 but in
a signiﬁcant number of patients, occlusive iliac disease, iliac
tortuosity and small vessel caliber precludes trans-femoral
approach. This issue is most commonly addressed through
the use of a retroperitoneal iliac conduit. In the multicenter
TAG thoracic endoprosthesis (W. L. Gore and Assoc, Flag-
staff, Ariz) trial and in an international survey of physicians
performing TEVAR, conduits were needed because of
access-related issues in 15% of patients.2,3 Conduit or
bypass for vascular access has become part of the standard
procedure and serves signiﬁcantly to expand the subset of
patients who undergo TEVAR.
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of TEVAR has not been thoroughly evaluated in a larger
population. In our paper, we analyzed the perioperative
morbidity and mortality associated with adjunctive iliac
conduit placement compared with conventional trans-
femoral approach during TEVAR based on the American
College of Surgeon National Surgical Quality Improvement
Program (ACS NSQIP) database.
METHODS
Data source
ACS NSQIP is a risk-adjusted data collection mechanism that
collects and analyzes clinical outcomes data. Participating
hospitals use their collected data to develop quality initia-
tives that improve surgical care and to identify elements in
provided healthcare that can be improved when compared
with other institutions. Currently more than 300 institutions
participate in this initiative. The ACS NSQIP collects data on
a variety of clinical variables, including preoperative risk
factors, intraoperative variables, and 30-day postoperative
mortality and morbidity outcomes for patients undergoing
major surgical procedures in both the inpatient and
outpatient setting. A site’s surgical clinical nurse reviewer
(SCR) using a variety of methods, including medical chart
abstraction, captures outcomes data. Vascular disease
speciﬁc data as well as anatomic data are not included in
the 2005e2010 ACS NSQIP database.Data selection
Using this database, we identiﬁed patients undergoing
elective TEVAR between 2005 and 2010.
Current Procedural Terminology (CPT, American Medical
Association, Chicago, Ill) codes used were 33881 and 33880,
which describe elective TEVAR and the “OTHER CPT” codes
34820 and 34833 used to describe conduit to facilitate
TEVAR.Risk factors and end-points
All risk factors available in the ACS NASQIP database were
evaluated and compared between groups. The primary
endpoint of the study was analysis of 30-day mortality.
Secondary endpoints included postoperative morbidity,
procedure-related complications and postoperative length
of stay. Composite endpoints were created to facilitate
a better understanding of the outcomes. Surgical compli-
cations (all surgical site infections, wound disruption,
bleeding requiring transfusion, Graft/Prosthesis/Flap failure,
peripheral nerve injury), renal complications (progressive
renal failure, acute renal failure), pulmonary complications
(pneumonia, unplanned intubation, respiratory insufﬁciency
requiring ventilation for 48 h), any sepsis (SIRS, sepsis,
septic shock), non-surgical complication (any complication
except surgical complications), cardiovascular complications
(pulmonary embolism, stroke/cerebrovascular event,
cardiac arrest, myocardial infarction, deep vein thrombosis/
thrombophlebitis) were analyzed. The variable “graftfailure” describes the mechanical failure of a stent graft or
prosthesis requiring return to the operating room, inter-
ventional radiology, or a balloon angioplasty within 30 days
of the operation.Statistical analysis
Categorical data were described using absolute numbers and
percent prevalence (%) in the study cohort. Continuous
variables were presented as means (standard deviation).
Categorical variables were compared by use of the Chi square
test or Fischer exact test for discrete values, while indepen-
dent 2-sample T-tests were used for normally distributed
continuous variables and the Wilcox rank sum test for non-
normally distributed continuous and ordinal variables.
Multivariable logistic regression models were used to
assess the association between type of repair (TEVAR with
conduit and TEVAR without conduit) and post-operative
mortality while controlling for possible confounders.
Confounders were identiﬁed by running regression models
with type of repair and one additional preoperative risk
factor or demographic variable at a time as predictors and
seeing how the results differed from running a logistic
model using type of repair alone. A change of more than
10% between the crude and adjusted odds ratio of type of
repair was used as evidence that the covariate was
a possible confounder. A ﬁnal logistic regression model was
run using type of repair groups and all confounders found in
this way.
Patients of age>90 years were transformed into 90 in the
database. A P value of less than 0.05 was considered the limit
for statistical signiﬁcance. Data were analyzed using SPSS
Statistics Version 19.0 (SPSS, IBM Inc). Odds ratios (OR) are
presented with 95% conﬁdence intervals (CI).
RESULTS
In the 2005e2010 ACS NSQIP database we identiﬁed 1154
patients who underwent elective repair of their TAA with or
without coverage of the left subclavian artery. 1037 patients
did not require use of a conduit (Group A, 89.9%) while 117
did (Group B, 10.1%). Female patients required conduit in
15.1% of the cases while males in 5.7% (p < 0.001). The
demographic data of the two groups are available in
Table 1. The two groups differed only with respect to history
of cardiac surgery or intervention, which was higher in the
non-conduit group, and smoking, which was more frequent
in the conduit group.
Duration of the procedure was on average longer in the
conduit group by 67 min (p < 0.001) and need for intra-
operative transfusion was higher (p ¼ 0.013) (Table 2).
Patients undergoing TEVAR with use of a conduit had
a signiﬁcantly higher risk of surgical complications
compared to patients without conduit (p¼ 0.035) as well as
a higher risk of any complication (p ¼ 0.025). Surgical site
infections were however not signiﬁcantly different between
the groups and need for transfusion was the factor
responsible for higher rate of surgical complications in the
conduit group (p ¼ 0.003). Risk for pulmonary, renal, septic
Table 1. Risk factors of patients undergoing endovascular aortic aneurysm repair with and without conduit.
TEVAR without conduit
N ¼ 1037
TEVAR with conduit
N ¼ 117
P value Total cohort
N ¼ 1154
Female 431(41.6%) 80(68.4%) <0.001 511(44.3%)
African-American 151(14.6%) 15(12.8%) 0.611 166(14.4%)
ASA I/II 39(3.8%) 3(2.6%) 0.737 42(3.6%)
ASA III 611(58.9%) 75(64.1%) 686(59.4%)
ASA IV 380(36.6%) 39(33.3%) 419(36.3%)
ASA V 6(0.6%) 0 6(0.5%)
Diabetes mellitus 142(13.7%) 11(9.4%) 0.193 153(13.3%)
Current smoker (within 1 year) 318(30.7%) 57(48.7%) <0.001 375(32.5%)
Alcohol abuse 39(3.8%) 6(5.1%) 0.469 45(3.9%)
Ventilator dependent 22(2.1%) 0 0.112 22(1.9%)
Severe COPD 199(19.2%) 27(23.1%) 0.315 226(19.6%)
Previous PCI 141(13.6%) 26(2.2%) 0.012 167(14.5%)
Previous cardiac surgery 236(22.8%) 17(14.5%) 0.04 253(21.9%)
Hypertension requiring medication 922(88.9%) 101(86.3%) 0.403 1023(88.6%)
History of revascularization/amputation 95(9.2%) 11(9.4%) 0.932 106(9.2%)
Rest pain/gangrene 9(0.9%) 1(0.9%) 0.988 10(0.9%)
On dialysis 34(3.3%) 3(2.6%) 0.677 37(3.2%)
CVA/Stroke with neurological deﬁcit 65(6.3%) 10(8.5%) 0.343 75(6.5%)
CVA/Stroke without neurological deﬁcit 68(6.6%) 5(4.3%) 0.336 73(6.3%)
Bleeding disorders 88(8.5%) 11(9.4%) 0.737 99(8.6%)
Transfusion >4 units PRBCs in 72 h before
surgery
14(1.4%) 0 0.206 14(1.2%)
Prior operation within 30 days 96(9.6%) 8(7.5%) 0.482 104(9.4%)
Preoperative sepsis 57(5.6%) 2(1.7%) 0.335 59(5.1)
Pack-years of smoking 30.85  35.5 43.36  34.85 0.001 32.53  35.81
Body mass index 27.57  6.12 26.16  5.06 0.17 27.43  6.03
Serum creatinine 1.27  0.96 1.18  1.15 0.395 1.26  0.98
eGFR 71.90  33.20 73.9  34.88 0.537 72.09  33.56
Hematocrit 36.83  5.87 36.73  5.19 0.860 36.88  5.79
Platelets 235.64  95.17 246.28  76.97 0.248 237.39  93.55
INR ratio 1.11  0.25 1.05  0.10 <0.001 1.10  0.24
N. Tsilimparis et al. 445and cardiovascular complications did not signiﬁcantly differ
between groups (Table 2). The complications of each group
are presented in detail in the Appendix 1.
Thirty-day mortality was 12% for patients who required
a conduit as an adjunctive procedure to TEVAR and 4.5% for
patients without conduit (p ¼ 0.001). The multivariate
analysis for mortality after controlling for relevant
confounders, showed a 3.8 times higher risk of death forTable 2. Operative parameters and 30-day outcome of patients who u
TEVAR without conduit
N ¼ 1037
Total operation time (min) 164.87  107.63
Number of RBC given intraoperative 0.70  2.12
Days of postoperative stay 6.62  8.8
Mortality 47(4.5%)
Any complication 248(23.9%)
Non-surgical complication 195(18.8%)
Surgical complication 103(9.9%)
Pulmonary complication 117(11.3%)
Renal complication 32(3.1%)
Cardiovascular complication 83(8%)
Graft failure 8(0.8%)
Any sepsis postoperative 31(3%)
Return to OR 104(10%)patients who had conduit placement (Table 3). Mean
postoperative length of stay in hospital was not signiﬁcantly
different among groups (p ¼ 0.247).
In the year 2005, there were only 6 patients with TEVAR
entered in the ACS NSQIP database. Between 2006 and
2010 the use of conduits during TEVAR had a constantly
declining rate resulting in a 6.5% use of iliac conduits in
2010, down from 17.9% in 2006 (Fig. 1).nderwent TEVAR with and without conduit.
TEVAR with conduit
N ¼ 117
P value Total cohort
231.97  97.33 <0.001 172.01  109.27
1.26  1.855 0.013 0.77  2.12
7.61  8.0 0.247 6.7  8.7
14(12%) 0.001 61(5.3%)
39 (33.3%) 0.025 287 (24.9%)
29(24.8%) 0.121 224(19.4%)
19(16.2%) 0.035 122(10.6%)
19(16.2%) 0.115 136(11.8%)
2(1.7%) 0.404 34(2.9%)
14(12%) 0.143 97(8.4%)
0 0.340 8(0.7%)
4(3.4%) 0.797 35(3%)
12(10.3%) 0.938 116(10.1%)
Table 3. Regression analysis for mortality in elective TEVAR.
Odds ratio (OR) 95% C.I. for OR
Use of conduit 3.78 1.98e7.43
Female gender 1.043 0.60e1.81
Coverage of the
left subclavian artery
1.816 1.055e3.126
ASA class IeII Reference Reference
ASA class III 0.65 0.15e2.90
ASA class IV 1.54 0.35e6.71
ASA class V 21.05 2.27e195.44
Ventilator dependent 4.15 1.34e12.90
TEVAR: Endovascular repair of thoracic aortic aneurysm.
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The present paper addresses the inﬂuence of iliac conduit
use on the outcomes of TEVAR. In an analysis of 1154
TEVAR patients who were entered over a 5-year period in
the ACS NSQIP database, we could demonstrate that the
use of conduits was independently associated with higher
mortality even after controlling for relevant confounders as
gender and intraoperative coverage of the left subclavian
artery (Odds ratio 3.8). Although the groups of patients with
and without conduit did not substantially differ with respect
to risk factors, it was obvious that female patients were
more likely to receive a conduit than males. Unfortunately
data concerning the anatomy of the aortic arch that could
lead to increased number of strokes and subsequent deaths
are not captured in the ACS NSQIP database. Patients
requiring conduit had a higher risk of bleeding and receiving
intra- and post-operative blood transfusions. Interestingly
there was no difference in wound infections as well as in
renal, cardiovascular complications and the composite
endpoint of pulmonary complications between groups,
although patients with conduit had a greater reintubation
risk in the early postoperative period. In this series patientsFigure 1. Use of conduits during endovasculareceiving conduits had a slightly higher rate of cerebrovas-
cular events (5.1% with conduits vs. 3.9% without conduits,
p ¼ 0.01).
The interpretation of these ﬁndings is a critical issue and
extreme caution is warranted not to imply that the use of
conduit itself is the cause of higher mortality.
Due to the nature of the database we can only speculate
on how the use of conduits inﬂuences mortality during
TEVAR. A major contributor to mortality could be the fact
that patients undergoing TEVAR already have a restricted
cardiac and respiratory function, so that a surgical proce-
dure even in the form of a retroperitoneal approach could
be relevant in overall outcome.
Another explanation could be of course that patients
with challenging vascular access have on the whole a more
challenging anatomy leading to more complications and/or
mortality. These anatomic factors including the morphology
of the arch are not captured in the ACS NSQIP database and
this represents of course one of the database’s limitations.
Despite technologic advances and device improvements,
the large sheaths required during TEVAR, represent a signiﬁ-
cant limitation in the setting of heavily calciﬁed or torturous
iliac arteries. A variety of ancillary techniques used to facili-
tate device navigation are available including simple iliac
artery angioplasty, retrograde external iliac artery endarter-
ectomy, placement of a covered stent followed by controlled
rupture of the iliac artery (endoconduit), and the construc-
tion of an open iliofemoral bypass conduit.7e9
Data from single- and multi-centered studies report the
incidence of access problems requiring use of open surgical
iliac conduit at 9e21% of patients undergoing TEVAR.2,4,10e12
Women are known to be associated with a higher risk of
access site complications due to their smaller access vessel
diameter and need of iliac conduits.11,13,14 However associa-
tion of outcome and use of iliac conduit was not speciﬁcally
investigated irrespective of gender in these studies. Etezadir repair of the thoracic aorta over time.
TEVAR
without
conduit
N ¼ 1037
TEVAR
with
conduit
N ¼ 117
P
value
Total
cohort
Superﬁcial SSI 13(1.3%) 2(1.7%) 0.680 15(1.3%)
Deep incisional
SSI
1(0.1%) 0 0.737 1(0.1%)
Organ/Space
SSI
2(0.2%) 0 0.634 2(0.2%)
Wound
disruption
3(0.3%) 0 0.560 3(0.3%)
Pneumonia 46(4.4%) 5(4.3%) 0.935 51(4.4%)
Unplanned
intubation
54(5.2%) 14(11.9%) 0.002 68(5.9%)
Ventilator>48 h 73(7.1%) 13(11.2%) 0.377 86(7.5%)
Pulmonary
embolism
8(0.8%) 0 0.635 8(0.7%)
Progressive
renal
insufﬁciency
11(1.1%) 0 0.263 11(1%)
Acute renal
failure
23(2.2%) 2(1.7%) 0.963 25(2.2%)
Urinary tract
infection
37(3.6%) 5(4.1%) 0.977 42(3.6%)
Stroke/
cerebrovascular
accident with
deﬁcit
40(3.9%) 6(5.1%) 0.011 46(4%)
Peripheral nerve
injury
7(0.7%) 1(0.9%) 0.824 8(0.7%)
Cardiac arrest 22(2.1%) 4(3.4%) 0.370 26(2.3%)
Myocardial
infarction
8(0.8%) 2(1.7%) 0.299 10(0.9%)
Bleeding requiring
transfusions
(intra-/post-
operative)
74(7.1%) 16(13.7%) 0.003 90(7.8%)
Deep vein
thrombosis/
thrombophlebitis
16(1.6%) 3(2.6%) 0.162 19(1.6%)
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conduits in 133 consecutive patients but were not able to
show a signiﬁcantly worse outcome in the 19 patients
requiring retroperitoneal iliac access.
Over the past ﬁve years, a signiﬁcant reduction in the use
of iliac conduits has occurred from 17.9% of elective TEVAR
cases in 2006 down to 6.5% in 2010. The reason for this is
likely due to the increasing use and experience with endo-
vascular techniques such as the so called “paving and
cracking” technique to overcome the issue of small and
calciﬁed iliac arteries. The use of endoconduits has been
increasing during TEVAR after ﬁrst description of the tech-
nique by Peterson and Matsumura in 2008.16 The time point
of introduction of this technique coincides with the decrease
in the use of open surgical conduits via retroperitoneal
access. This decreasing trendmay also be associated with the
experience gained in the ﬁeld by vascular surgeons over the
years, as well as by improved technology of the delivery
sheaths, such as adding hydrophilic coating to the outside of
the sheaths and making the sheaths more ﬂexible. The
hydrophilic coating has made the sheaths more lubricious
allowing them the ability to more easily traverse narrowed,
calciﬁed iliac arteries, and the increased ﬂexibility has
permitted better navigation through tortuous vessels.
The introduction of devices with lower proﬁle that would
facilitate access to the target vessels without the use of
endo- or conventional conduits has been eagerly antici-
pated. Most companies currently provide stent grafts that
come with or require a sheath of 22 French (F) to introduce
a stent graft of 31e34 mm of diameter and 24 F for larger
diameter devices. The next generation of thoracic devices
however is expected to decrease the crossing proﬁle below
the threshold of 22 F. The Zenith TX2 Low Proﬁle device
(Cook Medical, Indianapolis, IN) is currently under clinical
trial and allows introduction of a 32 mm stent graft through
an 18 F sheath.
LIMITATIONS
This is an observational study from a registry database.
Limitations of the study mainly involve missing variables
that are not captured in the ACS NSQIP database such as
aneurysm speciﬁc characteristics as well as the fact that
only patients who underwent open conduit are included.
The ACS NSQIP database was created to report data
collected from surgical patients in different specialties to
enhance quality of care by providing data for comparison.
Thus, limitations due to the database design are expected
when a speciﬁc surgical entity and issue is addressed.
Details on type of graft failure or reason for reintervention
are not available. Data were collected from over 400
hospitals in the United States so that a uniform pattern of
patient management, or indication for surgery and retro-
peritoneal conduit cannot be identiﬁed.
CONCLUSION
The use of iliac conduits to facilitate access for TEVAR is
associated with higher surgical complications and mortalityin comparison to patients who do not require conduits.
Female patients more frequently require iliac conduits
during TEVAR compared to men. This may contribute to the
worse overall outcomes for women during TEVAR as
described in industry-sponsored trials. The incidence of
conduit use has decreased threefold in the last ﬁve years
which may be in part due to the introduction of alternative
interventional techniques such as the use of endoconduits.
The current data, however, should not discourage vascular
surgeons from using conduits to establish safe access, but
rather make them aware of the higher associated morbidity
and mortality rates. Technological advances in sheath
manufacturing, such as hydrophilic coating, increased ﬂex-
ibility and reduced crossing proﬁles promise to simplify
device delivery and reduce access-related complications.
APPENDIX 1. COMPLICATIONS OF TEVAR WITH AND
WITHOUT CONDUIT IN DETAIL.
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